Limits...
XiangshaLiujunzi decoction alleviates the symptoms of functional dyspepsia by regulating brain-gut axis and production of neuropeptides.

Liu J, Li F, Tang XD, Ma J, Ma X, Ge DY, Li GM, Wang Y - BMC Complement Altern Med (2015)

Bottom Line: However, the response to gastric detention decreased.By contrast, XSLJZD decreased the mRNA expression of these neuropeptides in the hypothalamus.This finding can help elucidate the mechanism of FD and can provide further insight into the pharmacokinetics of XSLJZD.

View Article: PubMed Central - PubMed

Affiliation: School of Preclinical Medicine, Beijing University of Chinese Medicine, Beijing, China. lglangfang@sina.com.

ABSTRACT

Background: Chinese medicine xiangshaliujunzi decoction (XSLJZD) plays a key role in treating functional dyspepsia (FD), a common clinical gastrointestinal disorder. However, the mechanism of this disease is unclear. Brain-gut axis regulates food intake behaviour, and this regulatory mechanism is mediated by neuropeptides. Brain-gut axis impairment and neuropeptide alteration may be the pathological mechanisms of FD, and brain-gut axis regulation may influence the action of medicine.

Methods: In our experiment, the effect of XSLJZD on FD was evaluated in terms of food intake, sucrose preference test and electromyogram. Changes in neuropeptides [ghrelin, cholecystokinin (CCK) and vasoactive intestinal polypeptide (VIP)] were detected through immunohistochemistry, real-time PCR and ELISA.

Results: XSLJZD increased food intake and the percentage of sucrose preference (>75 %). However, the response to gastric detention decreased. Furthermore, XSLJZD increased ghrelin, CCK, VIP proteins and genes in the stomach. XSLJZD also increased ghrelin, CCK and VIP proteins in serum. By contrast, XSLJZD decreased the mRNA expression of these neuropeptides in the hypothalamus.

Conclusions: XSLJZD alleviated the symptoms of FD by upregulating the production of ghrelin, CCK and VIP and by increasing the levels of these neuropeptides in circulation. This finding can help elucidate the mechanism of FD and can provide further insight into the pharmacokinetics of XSLJZD.

No MeSH data available.


Related in: MedlinePlus

Expression of Ghrelin in stomach of each group. a Control group. b Model group. c XSLJZD-treated group. d Low-dose XSLJZD treated group. e Domperidone-treated group. Ghrelin was expressed as granular neuropetide in the cytoplasm of the stratum basale of the stomach (Tissue sections were viewed at 20× magnification.) Brown cells were positive for Ghrelin. Model group expressed lower Ghrelin than control group, XSLJZD significantly increased ghrelin of rats with FD
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4623916&req=5

Fig7: Expression of Ghrelin in stomach of each group. a Control group. b Model group. c XSLJZD-treated group. d Low-dose XSLJZD treated group. e Domperidone-treated group. Ghrelin was expressed as granular neuropetide in the cytoplasm of the stratum basale of the stomach (Tissue sections were viewed at 20× magnification.) Brown cells were positive for Ghrelin. Model group expressed lower Ghrelin than control group, XSLJZD significantly increased ghrelin of rats with FD

Mentions: Ghrelin, CCK-8 and VIP were expressed as granular neuropeptides in the cytoplasm of the hypothalamus (Figs. 4, 5 and 6) and the stratum basale of the stomach (Figs. 7, 8 and 9). The expressions of these neuropeptides were lower in the brain and in the stomach of rats with FD compared with those of the control rats. In the stomach and the hypothalamus, ghrelin, CCK-8 and VIP of the rats with FD were lower than those of the control rats (P <0.05; n = 3 in each group). Low-dose XSLJZD-treated groups did not significantly differ from the model group. However, XSLJZD significantly increased ghrelin, CCK-8 and VIP of rats with FD (P <0.05; n = 3). Ghrelin, CCK-8 and VIP of the domperidone-treated group were also higher than those of the model group, except for VIP in the hypothalamus (P <0.05; n = 3) (Table 2 and Fig. 10).Fig. 4


XiangshaLiujunzi decoction alleviates the symptoms of functional dyspepsia by regulating brain-gut axis and production of neuropeptides.

Liu J, Li F, Tang XD, Ma J, Ma X, Ge DY, Li GM, Wang Y - BMC Complement Altern Med (2015)

Expression of Ghrelin in stomach of each group. a Control group. b Model group. c XSLJZD-treated group. d Low-dose XSLJZD treated group. e Domperidone-treated group. Ghrelin was expressed as granular neuropetide in the cytoplasm of the stratum basale of the stomach (Tissue sections were viewed at 20× magnification.) Brown cells were positive for Ghrelin. Model group expressed lower Ghrelin than control group, XSLJZD significantly increased ghrelin of rats with FD
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4623916&req=5

Fig7: Expression of Ghrelin in stomach of each group. a Control group. b Model group. c XSLJZD-treated group. d Low-dose XSLJZD treated group. e Domperidone-treated group. Ghrelin was expressed as granular neuropetide in the cytoplasm of the stratum basale of the stomach (Tissue sections were viewed at 20× magnification.) Brown cells were positive for Ghrelin. Model group expressed lower Ghrelin than control group, XSLJZD significantly increased ghrelin of rats with FD
Mentions: Ghrelin, CCK-8 and VIP were expressed as granular neuropeptides in the cytoplasm of the hypothalamus (Figs. 4, 5 and 6) and the stratum basale of the stomach (Figs. 7, 8 and 9). The expressions of these neuropeptides were lower in the brain and in the stomach of rats with FD compared with those of the control rats. In the stomach and the hypothalamus, ghrelin, CCK-8 and VIP of the rats with FD were lower than those of the control rats (P <0.05; n = 3 in each group). Low-dose XSLJZD-treated groups did not significantly differ from the model group. However, XSLJZD significantly increased ghrelin, CCK-8 and VIP of rats with FD (P <0.05; n = 3). Ghrelin, CCK-8 and VIP of the domperidone-treated group were also higher than those of the model group, except for VIP in the hypothalamus (P <0.05; n = 3) (Table 2 and Fig. 10).Fig. 4

Bottom Line: However, the response to gastric detention decreased.By contrast, XSLJZD decreased the mRNA expression of these neuropeptides in the hypothalamus.This finding can help elucidate the mechanism of FD and can provide further insight into the pharmacokinetics of XSLJZD.

View Article: PubMed Central - PubMed

Affiliation: School of Preclinical Medicine, Beijing University of Chinese Medicine, Beijing, China. lglangfang@sina.com.

ABSTRACT

Background: Chinese medicine xiangshaliujunzi decoction (XSLJZD) plays a key role in treating functional dyspepsia (FD), a common clinical gastrointestinal disorder. However, the mechanism of this disease is unclear. Brain-gut axis regulates food intake behaviour, and this regulatory mechanism is mediated by neuropeptides. Brain-gut axis impairment and neuropeptide alteration may be the pathological mechanisms of FD, and brain-gut axis regulation may influence the action of medicine.

Methods: In our experiment, the effect of XSLJZD on FD was evaluated in terms of food intake, sucrose preference test and electromyogram. Changes in neuropeptides [ghrelin, cholecystokinin (CCK) and vasoactive intestinal polypeptide (VIP)] were detected through immunohistochemistry, real-time PCR and ELISA.

Results: XSLJZD increased food intake and the percentage of sucrose preference (>75 %). However, the response to gastric detention decreased. Furthermore, XSLJZD increased ghrelin, CCK, VIP proteins and genes in the stomach. XSLJZD also increased ghrelin, CCK and VIP proteins in serum. By contrast, XSLJZD decreased the mRNA expression of these neuropeptides in the hypothalamus.

Conclusions: XSLJZD alleviated the symptoms of FD by upregulating the production of ghrelin, CCK and VIP and by increasing the levels of these neuropeptides in circulation. This finding can help elucidate the mechanism of FD and can provide further insight into the pharmacokinetics of XSLJZD.

No MeSH data available.


Related in: MedlinePlus